Sonic Healthcare (SHL) Stock Overview
Offers medical diagnostic services, and administrative services and facilities to medical practitioners in Australia, the United States, Germany, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
SHL Community Fair Values
Create NarrativeSee what 118 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
AU$30
FV
35.5% undervalued intrinsic discount10.39%
Revenue growth p.a.
215
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Sonic Healthcare Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$19.34 |
| 52 Week High | AU$29.24 |
| 52 Week Low | AU$18.26 |
| Beta | 0.58 |
| 1 Month Change | 3.26% |
| 3 Month Change | -15.18% |
| 1 Year Change | -26.71% |
| 3 Year Change | -44.65% |
| 5 Year Change | -45.67% |
| Change since IPO | 19,240.00% |
Recent News & Updates
Narrative Update • Jun 04
SHL: Companion Diagnostics Partnership And Dividend Are Expected To Support Re Rating
Analysts have trimmed their price target for Sonic Healthcare by A$0.20 to reflect slightly adjusted assumptions around fair value, discount rate, revenue growth, profit margin and future P/E, while keeping the overall thesis broadly intact. What's in the News CellCarta and Sonic Healthcare USA have entered into a partnership to commercialize companion diagnostics through Sonic Healthcare's clinical laboratory network, with a focus on oncology, autoimmune disease and other precision medicine settings.Narrative Update • May 12
SHL: Upcoming A$0.45 Dividend Will Support Future Re Rating
Analysts have nudged their price target for Sonic Healthcare slightly lower to about A$24.98 from around A$25.26. The revision reflects updated assumptions for a higher discount rate, a modestly different revenue growth outlook, a steady profit margin profile and a slightly higher future P/E multiple.Narrative Update • Apr 27
SHL: Upcoming Dividend Will Support Future Re-Rating Despite Slightly Lower Fair Value
Analysts have trimmed their price target for Sonic Healthcare slightly, with updated fair value moving from around A$25.74 to about A$25.26, reflecting small adjustments to revenue growth, profit margin and future P/E assumptions. What's in the News Sonic Healthcare declared a dividend of A$0.45 per share for the six months ended 31 December 2025, giving investors clearer visibility on upcoming cash returns (Key Developments).
New Narrative • Apr 21
Sonic Healthcare Is Priced for Yesterday. Its AI Is Built for Tomorrow.
Sonic Healthcare stands as the world’s third-largest medical diagnostics company, operating an extensive network of pathology labs, radiology centers, and primary care medical practices across Australia, the US, Germany, Switzerland, and the UK. Founded in 1987, the company has spent over three decades executing a disciplined acquisition strategy to become a cornerstone of global healthcare infrastructure.Narrative Update • Apr 11
SHL: Upcoming Dividend And Stable Assumptions Will Support A Higher Future Multiple
Analysts have slightly adjusted their price targets for Sonic Healthcare, reflecting updated assumptions for revenue growth, profit margins and future P/E. These changes point to a refined view of fair value around A$25.74 per share.Recent updates
Narrative Update • Jun 04
SHL: Companion Diagnostics Partnership And Dividend Are Expected To Support Re Rating
Analysts have trimmed their price target for Sonic Healthcare by A$0.20 to reflect slightly adjusted assumptions around fair value, discount rate, revenue growth, profit margin and future P/E, while keeping the overall thesis broadly intact. What's in the News CellCarta and Sonic Healthcare USA have entered into a partnership to commercialize companion diagnostics through Sonic Healthcare's clinical laboratory network, with a focus on oncology, autoimmune disease and other precision medicine settings.Narrative Update • May 12
SHL: Upcoming A$0.45 Dividend Will Support Future Re Rating
Analysts have nudged their price target for Sonic Healthcare slightly lower to about A$24.98 from around A$25.26. The revision reflects updated assumptions for a higher discount rate, a modestly different revenue growth outlook, a steady profit margin profile and a slightly higher future P/E multiple.Narrative Update • Apr 27
SHL: Upcoming Dividend Will Support Future Re-Rating Despite Slightly Lower Fair Value
Analysts have trimmed their price target for Sonic Healthcare slightly, with updated fair value moving from around A$25.74 to about A$25.26, reflecting small adjustments to revenue growth, profit margin and future P/E assumptions. What's in the News Sonic Healthcare declared a dividend of A$0.45 per share for the six months ended 31 December 2025, giving investors clearer visibility on upcoming cash returns (Key Developments).New Narrative • Apr 21
Sonic Healthcare Is Priced for Yesterday. Its AI Is Built for Tomorrow.
Sonic Healthcare stands as the world’s third-largest medical diagnostics company, operating an extensive network of pathology labs, radiology centers, and primary care medical practices across Australia, the US, Germany, Switzerland, and the UK. Founded in 1987, the company has spent over three decades executing a disciplined acquisition strategy to become a cornerstone of global healthcare infrastructure.Narrative Update • Apr 11
SHL: Upcoming Dividend And Stable Assumptions Will Support A Higher Future Multiple
Analysts have slightly adjusted their price targets for Sonic Healthcare, reflecting updated assumptions for revenue growth, profit margins and future P/E. These changes point to a refined view of fair value around A$25.74 per share.Narrative Update • Mar 28
SHL: Upcoming Dividend And Conservative Assumptions Will Support A Higher Future Multiple
Analysts have nudged Sonic Healthcare's fair value estimate slightly lower, trimming their price target by about A$0.28 as small adjustments to revenue growth, profit margin assumptions and future P/E expectations feed into a more conservative valuation. What's in the News Sonic Healthcare declared a dividend of A$0.45 per share for the six months ended 31 December 2025, giving investors clarity on the upcoming income timeline.Narrative Update • Mar 13
SHL: Upcoming Dividend And Stable Margins Will Support A Higher Future Multiple
Analysts have trimmed their price target for Sonic Healthcare slightly to A$26.03 from A$26.15. This reflects modestly softer assumptions for revenue growth, profit margins and future P/E multiples, while keeping the discount rate unchanged.Narrative Update • Feb 27
SHL: Dividend Clarity And Steady Margins Will Support A Fair Future Multiple
Analysts have trimmed their 12 month price target for Sonic Healthcare by a small amount to A$26.15, reflecting updated assumptions for more moderate revenue growth, slightly higher profit margins and a modestly higher future P/E multiple. What's in the News Sonic Healthcare declared a dividend of A$0.45 per share for the six months ended December 31, 2025, giving investors clarity on upcoming income timing (Key Developments).Narrative Update • Feb 12
SHL: Modest Margin Support Will Sustain An Attractive Future Earnings Multiple
Analysts have trimmed their price target for Sonic Healthcare slightly, with fair value moving from A$26.84 to A$26.19, as updated assumptions around discount rate, revenue growth, profit margins and future P/E feed into a more cautious valuation framework. Valuation Changes Fair Value: revised from A$26.84 to A$26.19, a modest reduction in the assessed share valuation.Analysis Article • Feb 11
Returns On Capital At Sonic Healthcare (ASX:SHL) Have Stalled
What trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...
New Narrative • Feb 02
Radiology And Genetics Demand Will Transform This Diagnostics Consolidator Over The Next Decade
Catalysts About Sonic Healthcare Sonic Healthcare is a global medical diagnostics company focused on laboratory pathology, radiology and clinical services across multiple countries. What are the underlying business or industry changes driving this perspective?Narrative Update • Jan 29
SHL: Modest Margin Improvement Will Support Attractive Future Earnings Multiple
Analysts have trimmed their price expectations for Sonic Healthcare, reflecting a slightly lower fair value estimate to A$26.84 from A$27.68, along with updated assumptions for revenue growth, profit margins and future P/E levels. Valuation Changes Fair Value: trimmed from A$27.68 to A$26.84, a small reduction in the estimated fair value per share.Narrative Update • Jan 15
SHL: Higher Revenue Assumptions Will Support Attractive Future Earnings Multiple
Analysts have slightly reduced their price targets for Sonic Healthcare, reflecting updated fair value estimates of around $27.68, modestly higher revenue growth assumptions near 7.41% and minor adjustments to profit margin and P/E expectations. Valuation Changes Fair Value Estimate eased slightly from A$28.11 to A$27.68.Analysis Article • Dec 04
Is There An Opportunity With Sonic Healthcare Limited's (ASX:SHL) 34% Undervaluation?
Key Insights Sonic Healthcare's estimated fair value is AU$35.10 based on 2 Stage Free Cash Flow to Equity Current...Analysis Article • Nov 13
Sonic Healthcare Limited's (ASX:SHL) CEO Might Not Expect Shareholders To Be So Generous This Year
Key Insights Sonic Healthcare will host its Annual General Meeting on 20th of November Salary of AU$2.37m is part of...Analysis Article • Nov 02
Sonic Healthcare (ASX:SHL) Seems To Use Debt Quite Sensibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Oct 15
Sonic Healthcare (ASX:SHL) Has Some Way To Go To Become A Multi-Bagger
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Typically, we'll want to notice a...Analysis Article • Aug 26
Sonic Healthcare (ASX:SHL) Will Pay A Dividend Of A$0.63
The board of Sonic Healthcare Limited ( ASX:SHL ) has announced that it will pay a dividend on the 18th of September...Narrative Update • Aug 22
Recent Acquisitions And Cost Control Will Boost Future Efficiency In Pathology Testing
Sonic Healthcare’s lower consensus price target reflects a decline in net profit margin, partially offset by a slight improvement in forward P/E, resulting in a revised fair value estimate of A$28.25. What's in the News Sonic Healthcare announced an ordinary fully paid dividend of AUD 0.63 for the six months ending June 30, 2025.Analysis Article • Jul 10
Here's What's Concerning About Sonic Healthcare's (ASX:SHL) Returns On Capital
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Analysis Article • Jun 21
Subdued Growth No Barrier To Sonic Healthcare Limited's (ASX:SHL) Price
It's not a stretch to say that Sonic Healthcare Limited's ( ASX:SHL ) price-to-sales (or "P/S") ratio of 1.4x seems...
New Narrative • Feb 09
Medical Leadership Model And NHS Contracts Will Improve Future Service Quality
Strategic acquisitions and partnerships are set to drive growth and profitability through expanded market presence and operational synergies.Shareholder Returns
| SHL | AU Healthcare | AU Market | |
|---|---|---|---|
| 7D | -0.9% | -1.0% | -1.2% |
| 1Y | -26.7% | -11.8% | 0.8% |
Return vs Industry: SHL underperformed the Australian Healthcare industry which returned -11.8% over the past year.
Return vs Market: SHL underperformed the Australian Market which returned 0.8% over the past year.
Price Volatility
| SHL volatility | |
|---|---|
| SHL Average Weekly Movement | 3.3% |
| Healthcare Industry Average Movement | 6.1% |
| Market Average Movement | 10.2% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 4.1% |
Stable Share Price: SHL has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: SHL's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1934 | 45,000 | Jim Newcombe | www.sonichealthcare.com |
Sonic Healthcare Limited offers medical diagnostic services, and administrative services and facilities to medical practitioners in Australia, the United States, Germany, and internationally. The company provides laboratory medicine/pathology testing services, such as biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal testing, toxicology, and ancillary functions; and radiology services, including magnetic resonance imaging, computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry. It also offers primary care medical services comprising general practice clinics, occupational health services, skin cancer clinics, general practice IT solutions, and community-based healthcare services, as well as clinical trials services.
Sonic Healthcare Limited Fundamentals Summary
| SHL fundamental statistics | |
|---|---|
| Market cap | AU$9.56b |
| Earnings (TTM) | AU$539.40m |
| Revenue (TTM) | AU$10.42b |
17.7x
P/E Ratio0.9x
P/S RatioIs SHL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SHL income statement (TTM) | |
|---|---|
| Revenue | AU$10.42b |
| Cost of Revenue | AU$7.00b |
| Gross Profit | AU$3.42b |
| Other Expenses | AU$2.88b |
| Earnings | AU$539.40m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.09 |
| Gross Margin | 32.84% |
| Net Profit Margin | 5.18% |
| Debt/Equity Ratio | 47.6% |
How did SHL perform over the long term?
See historical performance and comparisonDividends
5.5%
Current Dividend Yield98%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/06 13:15 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sonic Healthcare Limited is covered by 25 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Saul Hadassin | Barrenjoey Markets Pty Limited |
| Benjamin Brayshaw | Barrenjoey Markets Pty Limited |
| Martyn Jacobs | Bell Potter |